

TABLE OF CONTENTS

Preface

G. Hartmann, S. Endres	vii
------------------------------	-----

Contributors

ix

Part I: The chemistry of antisense oligonucleotides

1. Chemical synthesis and purification of phosphorothioate antisense oligonucleotides
Y. S. Sanghvi, M. Andrade, R. R. Deshmukh, L. Holmberg, A. N. Scozzari,
D. L. Cole 3
2. How to choose optimal antisense targets in an mRNA
B. Schu, H. Brinkmeier 25

Part II: Antisense application *in vitro*

3. How to characterize and improve oligonucleotide uptake into leukocytes
M. Bidlingmaier, A. Krug, G. Hartmann 41
4. Strategies for targeted uptake of antisense oligonucleotides in hepatocytes
W.-B. Offenberger, J. Madon, C. Thoma, D. Moradpour, F. v. Weizsäcker,
H. E. Blum 57
5. How to exclude immunostimulatory and other nonantisense effects of antisense
oligonucleotides
A. M. Krieg 79
6. Testing antisense oligonucleotides in controlled cell culture assays
M. Flanagan 91
7. Inhibition of TNF synthesis by antisense oligonucleotides
M. Taylor, L. Kobzik 107
8. Inhibition of IGF-1 receptor expression by antisense oligonucleotides *in vitro*
and *in vivo*
M. Resnicoff 125

Part III: Antisense application *in vivo*

9. How to test antisense oligonucleotides in animals
R. Spanagel, C. Probst, D. C. Mash, T. Skutella 145
 10. Lipid-based carriers for the systemic delivery of antisense drugs
M. Webb 167
 11. Designing a clinical antisense study
F. E. Cotter, D. Fennell 191
- Index.....** 203